36476-88-7

Basic information

• Product Name: (1-BENZHYDRYLAZETIDIN-3-YL) METHANAMINE
• Synonyms: 1-DiphenylMethyl-3-(aMino...;1-(Diphenylmethyl)-3-azetidinemethanamine;3-Aminomethyl-1-diphenylmethylazetidinemethylamine;[1-(diphenylmethyl)azetidin-3-yl]methanamine;C-(1-BENZHYDRYL-AZETIDIN-3-YL)-METHYLAMINE;(1-BENZHYDRYLAZETIDIN-3-YL) METHANAMINE;RARECHEM AL BW 0782;1-Benzhydrylazetidine-3-methanamine
• CAS NO: 36476-88-7
• Molecular Formula: C₁₇H₂₀N₂
• Molecular Weight: 252.35
• Mol File: 36476-88-7.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 359℃
• Flash Point: 158℃
• Appearance: /
• Density: 1.102
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.608
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (1-BENZHYDRYLAZETIDIN-3-YL) METHANAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (1-BENZHYDRYLAZETIDIN-3-YL) METHANAMINE(36476-88-7)
• EPA Substance Registry System: (1-BENZHYDRYLAZETIDIN-3-YL) METHANAMINE(36476-88-7)

Safety Data

• Hazardous Substances Data: 36476-88-7(Hazardous Substances Data)

Usage

General Description

(1-Benzhydrylazetidin-3-yl) methanamine is a chemical compound with the molecular formula C21H24N2. It is a derivative of azetidine and methanamine, and it is commonly used as a building block in the synthesis of various pharmaceuticals and organic compounds. (1-BENZHYDRYLAZETIDIN-3-YL) METHANAMINE exhibits the structural features of both a cyclic amine and an aminal, and it possesses potential biological activity due to its unique structural attributes. It is important to handle this compound with care and in accordance with proper safety protocols and guidelines, as its properties and potential applications are still being studied and understood.

InChI:InChI=1/C17H20N2/c18-11-14-12-19(13-14)17(15-7-3-1-4-8-15)16-9-5-2-6-10-16/h1-10,14,17H,11-13,18H2

Upstream product

• 36476-86-5 1-(1,1-diphenylmethyl)azetidine-3-carbonitrile 
• 18621-17-5 1-(diphenylmethyl)-3-hydroxyazetidine 
• 33301-41-6 1-benzhydryl-3-azetidinyl methanesulfonate 

Downstream Products

• 55438-74-9 (1-benzhydrylazetidin-3-yl)-n,N-dimethylmethylamine 
• 321890-21-5 [1-(1,1-diphenylmethyl)azetidin-3-ylmethyl]dimethylamine 
• 91189-19-4 [[1-(diphenylmethyl)-3-azetidinyl]methyl]-carbamic acid 1,1-dimethylethyl ester 
• 1412978-13-2 3-[bis-(tert-butoxycarbonyl)aminomethyl]-1-(diphenylmethyl)azetidine 

Relevant articles and documents

PYRAZOLE DERIVATIVE

Not available

Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression

The invention relates to the use of pharmacologically valuable pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides according to general formula (I) in the treatment of tumors or for immunosuppression.

Alpha 1a adrenergic receptor antagonists

This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.